{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T06:32:31Z","timestamp":1775716351924,"version":"3.50.1"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T00:00:00Z","timestamp":1269907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T00:00:00Z","timestamp":1269907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1038\/nrclinonc.2010.41","type":"journal-article","created":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T05:37:06Z","timestamp":1269927426000},"page":"251-265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":210,"title":["The molecular pathology of cancer"],"prefix":"10.1038","volume":"7","author":[{"given":"Timothy J. R.","family":"Harris","sequence":"first","affiliation":[]},{"given":"Frank","family":"McCormick","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2010,3,30]]},"reference":[{"key":"BFnrclinonc201041_CR1","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1158\/0008-5472.CAN-07-3293","volume":"68","author":"IB Weinstein","year":"2008","unstructured":"Weinstein, I. B. & Joe, A. Oncogene addiction. Cancer Res. 68, 3077\u20133080 (2008).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201041_CR2","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1126\/science.1145720","volume":"318","author":"LD Wood","year":"2007","unstructured":"Wood, L. D.  et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108\u20131113 (2007).","journal-title":"Science"},{"key":"BFnrclinonc201041_CR3","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nbt1234","volume":"24","author":"N Papadopoulos","year":"2006","unstructured":"Papadopoulos, N., Kinzler, K. W. & Vogelstein, B. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies. Nat. Biotechnol. 24, 985\u2013995 (2006).","journal-title":"Nat. Biotechnol."},{"key":"BFnrclinonc201041_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.tig.2007.12.007","volume":"24","author":"ER Mardis","year":"2008","unstructured":"Mardis, E. R. The impact of next-generation sequencing technology on genetics. Trends Genet. 24, 133\u2013141 (2008).","journal-title":"Trends Genet."},{"key":"BFnrclinonc201041_CR5","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nature07943","volume":"458","author":"MR Stratton","year":"2009","unstructured":"Stratton, M. R., Campbell, P. & Futreal, P. A. The cancer genome. Nature 458, 719\u2013724 (2009).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR6","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nbt0308-256b","volume":"26","author":"N Siva","year":"2008","unstructured":"Siva, N. 1000 Genomes project. Nat. Biotechnol. 26, 256 (2008).","journal-title":"Nat. Biotechnol."},{"key":"BFnrclinonc201041_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrg2626","volume":"11","author":"ML Metzker","year":"2010","unstructured":"Metzker, M. L. Sequencing technologies\u2014the next generation. Nat. Rev. Genet. 11, 31\u201346 (2010).","journal-title":"Nat. Rev. Genet."},{"key":"BFnrclinonc201041_CR8","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/nature08489","volume":"46","author":"SP Shah","year":"2009","unstructured":"Shah, S. P.  et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 46 1, 809\u2013813 (2009).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nature08629","volume":"463","author":"ED Pleasance","year":"2010","unstructured":"Pleasance, E. D.  et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463, 184\u2013190 (2010).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nature08658","volume":"463","author":"ED Pleasance","year":"2010","unstructured":"Pleasance, E. D.  et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463, 191\u2013196 (2010).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR11","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.1561","volume":"27","author":"D Pushkarev","year":"2009","unstructured":"Pushkarev, D., Neff, N. F. & Quake, S. R. Single-molecule sequencing of an individual human genome. Nat. Biotechnol. 27, 847\u2013852 (2009).","journal-title":"Nat. Biotechnol."},{"key":"BFnrclinonc201041_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nbt0108-65","volume":"26","author":"M Stratton","year":"2008","unstructured":"Stratton, M. Genome resequencing and genetic variation. Nat. Biotechnol. 26, 65\u201366 (2008).","journal-title":"Nat. Biotechnol."},{"key":"BFnrclinonc201041_CR13","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nmeth0709-539","volume":"6","author":"N Blow","year":"2009","unstructured":"Blow, N. Genomics: catch me if you can. Nat. Methods 6, 539\u2013544 (2009).","journal-title":"Nat. Methods"},{"key":"BFnrclinonc201041_CR14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nature08250","volume":"461","author":"SB Ng","year":"2009","unstructured":"Ng, S. B.  et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature 461, 272\u2013276 (2009).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR15","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1172\/JCI34772","volume":"118","author":"TA Manolio","year":"2008","unstructured":"Manolio, T. A., Brooks, L. D. & Collins, F. S. A HapMap harvest of insights into the genetics of common disease. J. Clin. Invest. 118, 1590\u20131605 (2008).","journal-title":"J. Clin. Invest."},{"key":"BFnrclinonc201041_CR16","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMp0806284","volume":"360","author":"DB Goldstein","year":"2009","unstructured":"Goldstein, D. B. Common genetic variation and human traits. N. Engl. J. Med. 360, 1696\u20131698 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR17","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1056\/NEJMp0808934","volume":"360","author":"JN Hirschorn","year":"2009","unstructured":"Hirschorn, J. N. Genome-wide association studies\u2014illuminating biologic pathways. N. Engl. J. Med. 360, 1699\u20131701 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR18","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1056\/NEJMp0810107","volume":"360","author":"P Kraft","year":"2009","unstructured":"Kraft, P. & Hunter, D. J. Genetic risk prediction\u2014are we there yet? N. Engl. J. Med. 360, 1701\u20131702 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR19","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1056\/NEJMra0802968","volume":"359","author":"WD Foulkes","year":"2008","unstructured":"Foulkes, W. D. Inherited susceptibility to common cancers. N. Engl. J. Med. 359, 2143\u20132153 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR20","unstructured":"National Cancer Institute BRCA1 and BRCA2: cancer risk and genetic testing [online], (2009)."},{"key":"BFnrclinonc201041_CR21","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1126\/science.1156409","volume":"322","author":"D Altshuler","year":"2008","unstructured":"Altshuler, D., Daly, M. J. & Lander, E. S. Genetic mapping in human disease. Science 322, 881\u2013888 (2008).","journal-title":"Science"},{"key":"BFnrclinonc201041_CR22","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nature08494","volume":"461","author":"TA Manolio","year":"2009","unstructured":"Manolio, T. A.  et al. Finding the missing heritability of complex diseases. Nature 461, 747\u2013753 (2009).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR23","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1126\/science.319.5871.1782","volume":"319","author":"F Couzin","year":"2008","unstructured":"Couzin, F. MicroRNAs make big impression in disease after disease. Science 319, 1782\u20131784 (2008).","journal-title":"Science"},{"key":"BFnrclinonc201041_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature04687","volume":"441","author":"VN Ngo","year":"2006","unstructured":"Ngo, V. N.  et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441, 106\u2013110 (2006).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR25","doi-asserted-by":"publisher","first-page":"20798","DOI":"10.1073\/pnas.0806491106","volume":"105","author":"LT Lam","year":"2008","unstructured":"Lam, L. T.  et al. Compensatory IKK\u03b1 activation of classical NF-\u03baB signaling during IKK\u03b2 inhibition identified by an RNA interference sensitization screen. Proc. Natl Acad. Sci. USA 105, 20798\u201320803 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201041_CR26","doi-asserted-by":"publisher","first-page":"8695","DOI":"10.1073\/pnas.0903233106","volume":"106","author":"JW Tyner","year":"2009","unstructured":"Tyner, J. W.  et al. RNAi screen for rapid therapeutic target identification in leukemia patients. Proc. Natl Acad. Sci. USA 106, 8695\u20138700 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201041_CR27","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2009.05.006","volume":"1","author":"J Luo","year":"2009","unstructured":"Luo, J.  et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the RAS oncogene. Cell 1 37, 835\u2013848 (2009).","journal-title":"Cell"},{"key":"BFnrclinonc201041_CR28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie, D. A.  et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108\u2013112 (2009).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR29","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.cell.2009.03.017","volume":"13","author":"C Scholl","year":"2009","unstructured":"Scholl, C.  et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 13 7, 821\u2013834 (2009).","journal-title":"Cell"},{"key":"BFnrclinonc201041_CR30","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccr.2009.03.022","volume":"15","author":"A Singh","year":"2009","unstructured":"Singh, A.  et al. A gene expression signature associated with \u201cK-Ras addiction\u201d reveals regulators of EMT and tumor cell survival. Cancer Cell 15, 489\u2013500 (2009).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc201041_CR31","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1056\/NEJMra0802714","volume":"359","author":"RS Herbst","year":"2008","unstructured":"Herbst, R. S., Heymach, J. V. & Lippman, S. M. Lung cancer. N. Engl. J. Med. 359, 1367\u20131380 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR32","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/ng.109","volume":"40","author":"CI Amos","year":"2008","unstructured":"Amos, C. I.  et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet. 40, 616\u2013622 (2008).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201041_CR33","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nature06885","volume":"452","author":"RJ Hung","year":"2008","unstructured":"Hung, R. J.  et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452, 633\u2013637 (2008).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR34","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nature06846","volume":"452","author":"TE Thorgeirsson","year":"2008","unstructured":"Thorgeirsson, T. E.  et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452, 638\u2013642 (2008).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR35","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nm.1790","volume":"14","author":"K Shedden","year":"2008","unstructured":"Shedden, K.  et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat. Med. 14, 822\u2013827 (2008).","journal-title":"Nat. Med."},{"key":"BFnrclinonc201041_CR36","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/nm0808-812","volume":"14","author":"Y Xie","year":"2008","unstructured":"Xie, Y. & Minna, J. D. Predicting the future of people with lung cancer. Nat. Med. 14, 812\u2013813 (2008).","journal-title":"Nat. Med."},{"key":"BFnrclinonc201041_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ccr.2007.12.008","volume":"13","author":"SL Yu","year":"2008","unstructured":"Yu, S. L.  et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13, 48\u201357 (2008).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc201041_CR38","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1200\/JCO.2008.19.4134","volume":"27","author":"D Lebanony","year":"2009","unstructured":"Lebanony, D.  et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J. Clin. Oncol. 27, 2030\u20132037 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201041_CR39","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nrc2088","volume":"7","author":"SV Sharma","year":"2007","unstructured":"Sharma, S. V., Bell, D. W., Settleman, J. & Haber, D. A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7, 169\u2013181 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrclinonc201041_CR40","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok, T. S.  et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenococarcinoma. N. Engl. J. Med. 361, 947\u2013957 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR41","doi-asserted-by":"publisher","first-page":"20932","DOI":"10.1073\/pnas.0710370104","volume":"104","author":"J Bean","year":"2007","unstructured":"Bean, J.  et al. Met amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc. Natl Acad. Sci. USA 104, 20932\u201320937 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201041_CR42","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1141478","volume":"316","author":"JA Engelman","year":"2007","unstructured":"Engelman, J. A.  et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039\u20131043 (2007).","journal-title":"Science"},{"key":"BFnrclinonc201041_CR43","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1056\/NEJMoa0800668","volume":"359","author":"S Maheswaran","year":"2008","unstructured":"Maheswaran, S.  et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359, 366\u2013377 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR44","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1158\/1078-0432.CCR-07-2248","volume":"14","author":"JA Engelman","year":"2008","unstructured":"Engelman, J. A. & J\u00e4nne, P. A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 14, 2895\u20132899 (2008).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc201041_CR45","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda, M.  et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561\u2013566 (2007).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR46","doi-asserted-by":"publisher","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-07-6158","volume":"68","author":"YL Choi","year":"2008","unstructured":"Choi, Y. L.  et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 68, 4971\u20134976 (2008).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201041_CR47","unstructured":"Pfizer at the 45th annual ASCO annual meeting c-MET\/ALK inhibitor (PF-02341066) fact sheet [online], (2009)."},{"key":"BFnrclinonc201041_CR48","doi-asserted-by":"publisher","first-page":"5609","DOI":"10.1158\/1078-0432.CCR-08-2762","volume":"15","author":"YP Moss\u00e9","year":"2009","unstructured":"Moss\u00e9, Y. P., Wood, A. & Maris, J. M. Inhibition of ALK signaling for cancer therapy. Clin. Cancer Res. 15, 5609\u20135614 (2009).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc201041_CR49","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/sj.bjc.6604469","volume":"99","author":"JP Koivunen","year":"2008","unstructured":"Koivunen, J. P.  et al. Mutations in the LKB1 tumour suppressor are frequently found in tumours from Caucasian but not Asian lung cancer patients. Br. J. Cancer 99, 245\u2013252 (2008).","journal-title":"Br. J. Cancer"},{"key":"BFnrclinonc201041_CR50","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrc2676","volume":"9","author":"DB Shackleford","year":"2009","unstructured":"Shackleford, D. B. & Shaw, R. J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 9, 563\u2013575 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrclinonc201041_CR51","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","volume":"324","author":"MG Vander Heiden","year":"2009","unstructured":"Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029\u20131033 (2009).","journal-title":"Science"},{"key":"BFnrclinonc201041_CR52","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nature07423","volume":"455","author":"L Ding","year":"2008","unstructured":"Ding, L.  et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069\u20131074 (2008).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR53","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1073\/pnas.0712345105","volume":"105","author":"S Jones","year":"2008","unstructured":"Jones, S.  et al. Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl Acad. Sci. USA 105, 4283\u20134288 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201041_CR54","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc2645","volume":"9","author":"A Walther","year":"2009","unstructured":"Walther, A.  et al. Genetic prognostic and predictive markers in colorectal cancer. Nat. Rev. Cancer 9, 489\u2013499 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrclinonc201041_CR55","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/ng2089","volume":"39","author":"BW Zanke","year":"2007","unstructured":"Zanke, B. W.  et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat. Genet. 39, 989\u2013994 (2007).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201041_CR56","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/ng.111","volume":"40","author":"IP Tomlinson","year":"2008","unstructured":"Tomlinson, I. P.  et al. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosome 10p14 and 8q23.3. Nat. Genet. 40, 623\u2013630 (2008).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201041_CR57","unstructured":"O'Connell, M. J.  et al. Relationship between tumor gene expression and recurrence in patients with stage II\/III colon cancer treated with surgery + 5-FU\/LV in NSABP C-06: Consistency of results with two other independent studies [abstract 301]. 2008 Gastrointestinal Cancers Symposium"},{"key":"BFnrclinonc201041_CR58","doi-asserted-by":"publisher","first-page":"19432","DOI":"10.1073\/pnas.0806674105","volume":"105","author":"KS Garman","year":"2008","unstructured":"Garman, K. S.  et al. A genomic approach to colon cancer risk stratification yields biological insights into therapeutic opportunities. Proc. Natl Acad. Sci. USA 105, 19432\u201319437 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201041_CR59","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1200\/JCO.2008.20.6300","volume":"27","author":"F Innocenti","year":"2009","unstructured":"Innocenti, F.  et al. Comprehensive pharmacogenetic analysis of irinotecan, neutropenia, and pharmacokinetics. J. Clin. Oncol. 27, 2604\u20132614 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201041_CR60","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","volume":"3","author":"CS Karapetis","year":"2008","unstructured":"Karapetis, C. S.  et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 3 59, 1757\u20131765 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR61","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMe0806778","volume":"35","author":"WA Messersmith","year":"2008","unstructured":"Messersmith, W. A. & Ahnen, D. J. Targeting the EGFR in colorectal cancer. N. Engl. J. Med. 35 9, 1834\u20131836 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR62","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1056\/NEJMoa0808268","volume":"360","author":"J Tol","year":"2009","unstructured":"Tol, J.  et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360, 563\u2013572 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR63","doi-asserted-by":"publisher","first-page":"e7287","DOI":"10.1371\/journal.pone.0007287","volume":"4","author":"A Sartore-Bianchi","year":"2009","unstructured":"Sartore-Bianchi, A.  et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 4, e7287 (2009).","journal-title":"PLoS One"},{"key":"BFnrclinonc201041_CR64","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/nature05887","volume":"447","author":"DF Easton","year":"2007","unstructured":"Easton, D. F.  et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447, 1087\u20131093 (2007).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR65","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/ng2064","volume":"39","author":"SN Stacey","year":"2007","unstructured":"Stacey, S. N.  et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 39, 865\u2013869 (2007).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201041_CR66","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/ng.131","volume":"40","author":"SN Stacey","year":"2008","unstructured":"Stacey, S. N.  et al. Common variants on 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 40, 703\u2013706 (2008).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201041_CR67","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/ng.354","volume":"41","author":"S Ahmed","year":"2009","unstructured":"Ahmed, S.  et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat. Genet. 41, 585\u2013590 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201041_CR68","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/ng2075","volume":"39","author":"DJ Hunter","year":"2007","unstructured":"Hunter, D. J.  et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 39, 870\u2013874 (2007).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201041_CR69","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/ng.353","volume":"41","author":"G Thomas","year":"2009","unstructured":"Thomas, G.  et al. A multstage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat. Genet. 41, 579\u2013584 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201041_CR70","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/nrd2656","volume":"7","author":"A Vazquez","year":"2008","unstructured":"Vazquez, A., Bond, E. E., Levine, A. J. & Bond, G. L. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat. Rev. Drug Discov. 7, 979\u2013987 (2008).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrclinonc201041_CR71","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou, C. M.  et al. Molecular portraits of human breast tumours. Nature 406, 747\u2013752 (2000).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR72","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/S0140-6736(03)13322-3","volume":"361","author":"S Ramaswamy","year":"2003","unstructured":"Ramaswamy, S. & Perou, C. M. DNA microarrays in breast cancer: the promise of personalised medicine. Lancet 361, 1576\u20131577 (2003).","journal-title":"Lancet"},{"key":"BFnrclinonc201041_CR73","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMra0801289","volume":"360","author":"C Sotiriou","year":"2009","unstructured":"Sotiriou, C. & Pusztai, L. Gene expression signatures in breast cancer. N. Engl. J. Med. 360, 790\u2013800 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR74","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H.  et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR75","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1200\/JCO.2008.19.7681","volume":"27","author":"S Kummar","year":"2009","unstructured":"Kummar, S.  et al. Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J. Clin. Oncol. 27, 2705\u20132711 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201041_CR76","doi-asserted-by":"publisher","first-page":"7006","DOI":"10.1158\/0008-5472.CAN-08-0599","volume":"68","author":"M Dalla Palma","year":"2008","unstructured":"Dalla Palma, M.  et al. The relative contribution of point mutations and genomic rearrangments in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer Res. 68, 7006\u20137014 (2008).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201041_CR77","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong, P. C.  et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123\u2013134 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR78","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1056\/NEJMe0903044","volume":"361","author":"JD Inglehart","year":"2009","unstructured":"Inglehart, J. D. & Silver, D. P. Synthetic lethality\u2014a new direction in cancer drug development. N. Engl. J. Med. 361, 189\u2013191 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR79","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1038\/emboj.2008.61","volume":"27","author":"NC Turner","year":"2008","unstructured":"Turner, N. C.  et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 27, 1368\u20131377 (2008).","journal-title":"EMBO J."},{"key":"BFnrclinonc201041_CR80","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/emmm.200900041","volume":"1","author":"AM Mendes-Pereira","year":"2009","unstructured":"Mendes-Pereira, A. M.  et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1, 315\u2013322 (2009).","journal-title":"EMBO Mol. Med."},{"key":"BFnrclinonc201041_CR81","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nrc2683","volume":"9","author":"JM Hoskins","year":"2009","unstructured":"Hoskins, J. M., Carey, L. & McLeod, H. L. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 9, 576\u2013586 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrclinonc201041_CR82","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1002\/cncr.23373","volume":"112","author":"MA Dall'Era","year":"2008","unstructured":"Dall'Era, M. A.  et al. Active surveillance for early-stage prostate cancer: review of current literature. Cancer 112, 1650\u20131659 (2008).","journal-title":"Cancer"},{"key":"BFnrclinonc201041_CR83","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/ng.450","volume":"4","author":"RA Eeles","year":"2009","unstructured":"Eeles, R. A.  et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat. Genet. 4 1, 1116\u20131121 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201041_CR84","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ccr.2008.11.008","volume":"14","author":"BW Freie","year":"2008","unstructured":"Freie, B. W. & Eisenman, R. N. Ratcheting Myc. Cancer Cell 14, 425\u2013426 (2008).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc201041_CR85","doi-asserted-by":"publisher","first-page":"e1000597","DOI":"10.1371\/journal.pgen.1000597","volume":"5","author":"L Jia","year":"2009","unstructured":"Jia, L.  et al. Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet. 5, e1000597 (2009).","journal-title":"PLoS Genet."},{"key":"BFnrclinonc201041_CR86","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/ng.403","volume":"41","author":"MM Pomerantz","year":"2009","unstructured":"Pomerantz, M. M.  et al. The 8q24 cancer risk variant rs6983267 shows long range interaction with MYC in colorectal cancer. Nat. Genet. 41, 882\u2013884 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201041_CR87","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1073\/pnas.0906067107","volume":"107","author":"J Sotelo","year":"2010","unstructured":"Sotelo, J.  et al. Long-range enhancers on 8q24 regulate cMyc. Proc. Natl Acad. Sci. USA 107, 3001\u20133005 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201041_CR88","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/ng.406","volume":"41","author":"S Tuupanen","year":"2009","unstructured":"Tuupanen, S.  et al. The common colorectal cancer predisposition SNP rs698267 at chromosome 8p24 confers potential to enhanced Wnt signaling. Nat. Genet. 41, 885\u2013890 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201041_CR89","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1056\/NEJMoa075819","volume":"35","author":"SL Zheng","year":"2008","unstructured":"Zheng, S. L.  et al. Cumulative association of five genetic variants with prostate cancer. N. Engl. J. Med. 35 8, 910\u2013919 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR90","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/ng.90","volume":"40","author":"RA Eeles","year":"2008","unstructured":"Eeles, R. A.  et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet. 40, 316\u2013321 (2008).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201041_CR91","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/ng.91","volume":"40","author":"G Thomas","year":"2008","unstructured":"Thomas, G.  et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat. Genet. 40, 310\u2013315 (2008).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201041_CR92","doi-asserted-by":"publisher","first-page":"7933","DOI":"10.1073\/pnas.0902104106","volume":"106","author":"H Lou","year":"2009","unstructured":"Lou, H.  et al. Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc. Natl Acad. Sci. USA 106, 7933\u20137938 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201041_CR93","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1158\/0008-5472.CAN-07-6154","volume":"68","author":"R Mehra","year":"2008","unstructured":"Mehra, R.  et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 68, 3584\u20133590 (2008).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201041_CR94","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/modpathol.2008.96","volume":"21","author":"M Yashimoto","year":"2008","unstructured":"Yashimoto, M.  et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Mod. Pathol. 21, 1451\u20131460 (2008).","journal-title":"Mod. Pathol."},{"key":"BFnrclinonc201041_CR95","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nrc2402","volume":"8","author":"C Kumar-Sinha","year":"2008","unstructured":"Kumar-Sinha, C., Tomlins, S. A. & Chinnaiyan, A. M. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer 8, 497\u2013511 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrclinonc201041_CR96","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/ng0509-509","volume":"41","author":"JA Squire","year":"2009","unstructured":"Squire, J. A. TMPRSS2-ERG and PTEN loss in prostate cancer. Nat. Genet. 41, 509\u2013510 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201041_CR97","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nrg2507","volume":"10","author":"J Witte","year":"2009","unstructured":"Witte, J. Prostate cancer genomics: towards a new understanding. Nat. Rev. Genet. 10, 77\u201382 (2009).","journal-title":"Nat. Rev. Genet."},{"key":"BFnrclinonc201041_CR98","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00439-009-0715-9","volume":"126","author":"KD Meyle","year":"2009","unstructured":"Meyle, K. D. & Guldberg, P. Genetic risk factors for melanoma. Hum. Genet. 126, 499\u2013510 (2009).","journal-title":"Hum. Genet."},{"key":"BFnrclinonc201041_CR99","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/ng.411","volume":"41","author":"DT Bishop","year":"2009","unstructured":"Bishop, D. T.  et al. Genome-wide association study identifies three loci associated with melanoma risk. Nat. Genet. 41, 920\u2013925 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201041_CR100","doi-asserted-by":"publisher","first-page":"6268","DOI":"10.1073\/pnas.0901185106","volume":"106","author":"M Kashani-Sabet","year":"2009","unstructured":"Kashani-Sabet, M.  et al. A multi-marker assay to distinguish malignant melanoma from benign nevi. Proc. Natl Acad. Sci. USA 106, 6268\u20136272 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201041_CR101","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1073\/pnas.0711741105","volume":"105","author":"J Tsai","year":"2008","unstructured":"Tsai, J.  et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041\u20133046 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"7287","key":"BFnrclinonc201041_CR102","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature08833","volume":"464","author":"Georgia Hatzivassiliou","year":"2010","unstructured":"Hatzivassiliou, G.  et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature doi:10.1038\/nature08833","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR103","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/ng.438","volume":"41","author":"TD Prickett","year":"2009","unstructured":"Prickett, T. D.  et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat. Genet. 41, 1127\u20131132 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201041_CR104","doi-asserted-by":"publisher","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","volume":"24","author":"JA Curtin","year":"2006","unstructured":"Curtin, J. A., Busam, K., Pinkel, D. & Bastian, B. C. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 4340\u20134346 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201041_CR105","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/89044","volume":"7","author":"J Khan","year":"2001","unstructured":"Khan, J.  et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat. Med. 7, 673\u2013679 (2001).","journal-title":"Nat. Med."},{"key":"BFnrclinonc201041_CR106","first-page":"3395","volume":"119","author":"JG Taylor","year":"2009","unstructured":"Taylor, J. G.  et al. FGFR4 is a mutationally activated oncogene that promotes metastasis in rhabdomyosarcoma. J. Clin. Invest. 119, 3395\u20133406 (2009).","journal-title":"J. Clin. Invest."},{"key":"BFnrclinonc201041_CR107","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/ng.374","volume":"41","author":"M Capasso","year":"2009","unstructured":"Capasso, M.  et al. Common variants in BARD1 influence susceptibility to high risk neuroblastoma. Nat. Genet. 41, 718\u2013723 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201041_CR108","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.1158\/0008-5472.CAN-04-0695","volume":"64","author":"JS Wei","year":"2004","unstructured":"Wei, J. S.  et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res. 64, 6883\u20136891 (2004).","journal-title":"Cancer Res."},{"key":"BFnrclinonc201041_CR109","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ccr.2005.03.019","volume":"7","author":"M Ohira","year":"2005","unstructured":"Ohira, M.  et al. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 7, 337\u2013350 (2005).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc201041_CR110","doi-asserted-by":"publisher","first-page":"7902","DOI":"10.1038\/sj.onc.1208936","volume":"24","author":"A Schramm","year":"2005","unstructured":"Schramm, A.  et al. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 24, 7902\u20137912 (2005).","journal-title":"Oncogene"},{"key":"BFnrclinonc201041_CR111","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/jnci\/djj330","volume":"98","author":"S Asgharzadeh","year":"2006","unstructured":"Asgharzadeh, S.  et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J. Natl Cancer Inst. 98, 1193\u20131203 (2006).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201041_CR112","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.1200\/JCO.2006.06.1879","volume":"24","author":"A Oberthuer","year":"2006","unstructured":"Oberthuer, A.  et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J. Clin. Oncol. 24, 5070\u20135078 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201041_CR113","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/nature07399","volume":"455","author":"Y Chen","year":"2008","unstructured":"Chen, Y.  et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971\u2013974 (2008).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR114","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/nature07397","volume":"455","author":"RE George","year":"2008","unstructured":"George, R. E.  et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975\u2013978 (2008).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR115","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature07398","volume":"455","author":"I Janoueix-Lerosy","year":"2008","unstructured":"Janoueix-Lerosy, I.  et al. Somatic and germline mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967\u2013970 (2008).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR116","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc2291","volume":"8","author":"R Chiarle","year":"2008","unstructured":"Chiarle, R., Voena, C., Ambrogio, C., Piva, R. & Inghirami, G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat. Rev. Cancer 8, 11\u201323 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrclinonc201041_CR117","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa055351","volume":"354","author":"M Hummel","year":"2006","unstructured":"Hummel, M.  et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N. Engl. J. Med. 354, 2419\u20132430 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR118","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa055759","volume":"354","author":"SS Dave","year":"2006","unstructured":"Dave, S. S.  et al. Molecular diagnosis of Burkitt's lymphoma. N. Engl. J. Med. 354, 2431\u20132442 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR119","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0065-2776(05)87005-1","volume":"87","author":"LM Staudt","year":"2005","unstructured":"Staudt, L. M. & Dave, S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv. Immunol. 87, 163\u2013208 (2005).","journal-title":"Adv. Immunol."},{"key":"BFnrclinonc201041_CR120","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","volume":"113","author":"K Dunleavy","year":"2009","unstructured":"Dunleavy, K.  et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113, 6069\u20136076 (2009).","journal-title":"Blood"},{"key":"BFnrclinonc201041_CR121","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","volume":"359","author":"G Lenz","year":"2008","unstructured":"Lenz, G.  et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 359, 2313\u20132323 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR122","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1126\/science.1153629","volume":"319","author":"G Lenz","year":"2008","unstructured":"Lenz, G.  et al. Oncogenic CARD 11 mutations in human diffuse large B cell lymphoma. Science 319, 1676\u20131679 (2008).","journal-title":"Science"},{"key":"BFnrclinonc201041_CR123","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nature07968","volume":"459","author":"M Compagno","year":"2009","unstructured":"Compagno, M.  et al. Mutations of multiple genes cause deregulation of NF-\u03baB in diffuse large B cell lymphoma. Nature 459, 717\u2013722 (2009).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR124","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nature07969","volume":"459","author":"M Kato","year":"2009","unstructured":"Kato, M.  et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 459, 712\u2013716 (2009).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR125","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrd2781","volume":"8","author":"V Baud","year":"2009","unstructured":"Baud, V. & Karin, M. Is NF-\u03baB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 8, 33\u201340 (2009).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrclinonc201041_CR126","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nature07884","volume":"458","author":"TA Soucy","year":"2009","unstructured":"Soucy, T. A.  et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732\u2013736 (2009).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR127","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1056\/NEJMra020067","volume":"348","author":"LM Staudt","year":"2003","unstructured":"Staudt, L. M. Molecular diagnosis of hematologic cancers. N. Engl. J. Med. 348, 1777\u20131785 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR128","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/nm1009-1153","volume":"15","author":"N Lydon","year":"2009","unstructured":"Lydon, N. Attacking cancer at its foundation. Nat. Med. 15, 1153\u20131157 (2009).","journal-title":"Nat. Med."},{"key":"BFnrclinonc201041_CR129","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1172\/JCI30890","volume":"117","author":"NP Shah","year":"2007","unstructured":"Shah, N. P.  et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Invest. 117, 2562\u20132569 (2007).","journal-title":"J. Clin. Invest."},{"key":"BFnrclinonc201041_CR130","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nrc2559","volume":"9","author":"J Zhang","year":"2009","unstructured":"Zhang, J., Yang, P. L. & Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28\u201339 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrclinonc201041_CR131","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O'Hare","year":"2009","unstructured":"O'Hare, T.  et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16, 401\u2013412 (2009).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc201041_CR132","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1158\/1078-0432.CCR-08-1123","volume":"1","author":"S Meshinchi","year":"2009","unstructured":"Meshinchi, S. & Appelbaum, F. R. Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin. Cancer Res. 1 5, 4263\u20134269 (2009).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc201041_CR133","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccr.2007.11.005","volume":"12","author":"S Fr\u00f6hling","year":"2007","unstructured":"Fr\u00f6hling, S.  et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 12, 501\u2013513 (2007).","journal-title":"Cancer Cell"},{"key":"BFnrclinonc201041_CR134","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1172\/JCI38248","volume":"1","author":"JE Payton","year":"2009","unstructured":"Payton, J. E.  et al. High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. J. Clin. Invest. 1 19, 1714\u20131726 (2009).","journal-title":"J. Clin. Invest."},{"key":"BFnrclinonc201041_CR135","doi-asserted-by":"publisher","first-page":"12944","DOI":"10.1073\/pnas.0903142106","volume":"106","author":"I Radtke","year":"2009","unstructured":"Radtke, I.  et al. Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc. Natl Acad. Sci. USA 106, 12944\u201312949 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrclinonc201041_CR136","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/nature07485","volume":"456","author":"TJ Ley","year":"2008","unstructured":"Ley, T. J.  et al. DNA sequencing of a cytogenetically normal acute myeloid leukemia genome. Nature 456, 66\u201372 (2008).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR137","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","volume":"10","author":"ER Mardis","year":"2009","unstructured":"Mardis, E. R.  et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 10, 1058\u20131066 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR138","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1126\/science.1164266","volume":"32","author":"CG Mullighan","year":"2008","unstructured":"Mullighan, C. G.  et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 32 2, 1377\u20131380 (2008).","journal-title":"Science"},{"key":"BFnrclinonc201041_CR139","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jama.2009.7","volume":"301","author":"JJ Yang","year":"2009","unstructured":"Yang, J. J.  et al. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastoic leukemia. JAMA 301, 393\u2013403 (2009).","journal-title":"JAMA"},{"key":"BFnrclinonc201041_CR140","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1056\/NEJMoa0808253","volume":"360","author":"CG Mullighan","year":"2009","unstructured":"Mullighan, C. G.  et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N. Engl. J. Med. 360, 470\u2013480 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR141","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/ng.430","volume":"41","author":"E Papaemmanuil","year":"2009","unstructured":"Papaemmanuil, E.  et al. Loci on 7p12.2 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat. Genet. 41, 1006\u20131010 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrclinonc201041_CR142","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1146\/annurev.med.59.061506.154159","volume":"59","author":"KJ Morgan","year":"2008","unstructured":"Morgan, K. J. & Gilliland, D. G. A role for Jak2 mutations in myeloproliferative diseases. Annu. Rev. Med. 59, 213\u2013222 (2008).","journal-title":"Annu. Rev. Med."},{"key":"BFnrclinonc201041_CR143","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","volume":"360","author":"F Delhommeau","year":"2009","unstructured":"Delhommeau, F.  et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289\u20132301 (2009).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"BFnrclinonc201041_CR144","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1182\/asheducation-2009.1.636","volume":"2009","author":"S. Verstovsek","year":"2009","unstructured":"Verstovsek, S. Therapeutic potential of JAK2 inhibitors. Hematology Am. Soc. Hematol. Educ. Program 636\u2013642 (2009).","journal-title":"Hematology"},{"key":"BFnrclinonc201041_CR145","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1182\/blood-2002-10-3306","volume":"101","author":"A Wiestner","year":"2003","unstructured":"Wiestner, A.  et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome and distinct gene expression profile. Blood 101, 4944\u20134951 (2003).","journal-title":"Blood"},{"key":"BFnrclinonc201041_CR146","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1182\/blood-2007-05-092882","volume":"112","author":"LZ Rassenti","year":"2008","unstructured":"Rassenti, L. Z.  et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 112, 1923\u20131930 (2008).","journal-title":"Blood"},{"key":"BFnrclinonc201041_CR147","doi-asserted-by":"publisher","first-page":"5848","DOI":"10.1200\/JCO.2009.24.0317","volume":"27","author":"M Iorio","year":"2009","unstructured":"Iorio, M. V & Croce, C. M. MicroRNAs in cancer: small molecules with a huge impact. J. Clin. Oncol. 27, 5848\u20135856 (2009).","journal-title":"J. Clin. Oncol."},{"key":"BFnrclinonc201041_CR148","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/nrg2634","volume":"10","author":"CM Croce","year":"2009","unstructured":"Croce, C. M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 10, 704\u2013714 (2009).","journal-title":"Nat. Rev. Genet."},{"key":"BFnrclinonc201041_CR149","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.1158\/1078-0432.CCR-09-0913","volume":"15","author":"W Pao","year":"2009","unstructured":"Pao, W.  et al. Integration of molecular profiling into the lung cancer clinic. Clin. Cancer Res. 15, 5317\u20135322 (2009).","journal-title":"Clin. Cancer Res."},{"key":"BFnrclinonc201041_CR150","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman, J. A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 9, 550\u2013562 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnrclinonc201041_CR151","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrd2926","volume":"8","author":"P Liu","year":"2009","unstructured":"Liu, P.  et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627\u2013644 (2009).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrclinonc201041_CR152","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMsa0900592","volume":"360","author":"AK Jha","year":"2009","unstructured":"Jha, A. K.  et al. Use of electronic health records in US hospitals. N. Engl. J. Med. 360, 1628\u20131638 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR153","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1056\/NEJMp0801736","volume":"358","author":"R Steinbrook","year":"2008","unstructured":"Steinbrook, R. Personally controlled online health data\u2014the next big thing in medical care? N. Engl. J. Med. 358, 1653\u20131656 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR154","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature06913","volume":"452","author":"CL Sawyers","year":"2008","unstructured":"Sawyers, C. L. The cancer biomarker problem. Nature 452, 548\u2013552 (2008).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR155","first-page":"108","volume":"85","author":"MG Aspinall","year":"2007","unstructured":"Aspinall, M. G. & Hamermesh, R. G. Realizing the promise of personalized medicine. Harv. Bus. Rev. 85, 108\u2013117 (2007).","journal-title":"Harv. Bus. Rev."},{"key":"BFnrclinonc201041_CR156","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nrg2544","volume":"1","author":"JP Ioannidis","year":"2009","unstructured":"Ioannidis, J. P., Thomas, G. & Daly, M. J. Validating, augmenting and refining genome-wide association signals. Nat. Rev. Genet. 1 0, 318\u2013329 (2009).","journal-title":"Nat. Rev. Genet."},{"key":"BFnrclinonc201041_CR157","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nature04406","volume":"4","author":"C Nusbaum","year":"2006","unstructured":"Nusbaum, C.  et al. DNA sequence and analysis of human chromosome 8. Nature 4 39, 331\u2013335 (2006).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR158","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature07484","volume":"456","author":"J Wang","year":"2008","unstructured":"Wang, J.  et al. The diploid genome sequence of an Asian individual. Nature 456, 60\u201365 (2008).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR159","unstructured":"The 1000 Genomes Project 1000 Genomes\u2014a deep catalog of human genetic variation [online], (2010)."},{"key":"BFnrclinonc201041_CR160","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/nature08211","volume":"460","author":"JI Kim","year":"2009","unstructured":"Kim, J. I.  et al. A highly annotated whole genome sequence of a Korean individual. Nature 460, 1011\u20131016 (2009).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR161","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00439-008-0535-3","volume":"124","author":"M Yeager","year":"2008","unstructured":"Yeager, M.  et al. Comprehensive resequence analysis of a 136\u00a0kb region of human chromosome 8q24 associated with prostate and colon cancers. Hum. Genet. 124, 161\u2013170 (2008).","journal-title":"Hum. Genet."},{"key":"BFnrclinonc201041_CR162","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/462843a","volume":"462","author":"E Dolgin","year":"2009","unstructured":"Dolgin, E. Human genomics: The genome finishers. Nature 462, 843\u2013845 (2009).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR163","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1056\/NEJMsa0708739","volume":"358","author":"PD Pharaoh","year":"2008","unstructured":"Pharaoh, P. D., Antoniou, A. C., Easton, D. F. & Ponder, B. A. Polygenes, risk prediction and targeted prevention of breast cancer. N. Engl. J. Med. 358, 2796\u20132803 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrclinonc201041_CR164","unstructured":"GenomeWeb Scripps starts genomics study of breast cancer variants [online], (2009)."},{"key":"BFnrclinonc201041_CR165","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/461724a","volume":"461","author":"PC Ng","year":"2009","unstructured":"Ng, P. C., Murray, S. S., Levy, S. & Venter, J. C. An agenda for personalized medicine. Nature 461, 724\u2013726 (2009).","journal-title":"Nature"},{"key":"BFnrclinonc201041_CR166","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(00)04136-2","volume":"357","author":"P Vineis","year":"2001","unstructured":"Vineis, P., Schulte, P. & McMichael, A. J. Misconceptions about the use of genetic tests in populations. Lancet 357, 709\u2013712 (2001).","journal-title":"Lancet"}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2010.41.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2010.41","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2010.41.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T12:07:29Z","timestamp":1650370049000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2010.41"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,30]]},"references-count":166,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["BFnrclinonc201041"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2010.41","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,30]]},"assertion":[{"value":"30 March 2010","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T. J. R. Harris has worked as a consultant for Bionomics and BG Medicine, and is also a director of BG Medicine. F. McCormick is a director of Exelixis. He is also a director of Onyx and has worked as a consultant for this company. F. McCormick has also received research support from Daiichi Sankyo.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}